Anna-Lena Geissler
Overview
Explore the profile of Anna-Lena Geissler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoefflin R, Lazarou A, Hess M, Reiser M, Wehrle J, Metzger P, et al.
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33800365
Molecular precision oncology faces two major challenges: first, to identify relevant and actionable molecular variants in a rapidly changing field and second, to provide access to a broad patient population....
2.
Hoefflin R, Geissler A, Fritsch R, Claus R, Wehrle J, Metzger P, et al.
JCO Precis Oncol
. 2020 Sep;
2.
PMID: 32913998
Purpose: Dramatic advances in our understanding of the molecular pathophysiology of cancer, along with a rapidly expanding portfolio of molecular targeted drugs, have led to a paradigm shift toward personalized,...
3.
Geissler A, Geissler M, Kottmann D, Lutz L, Fichter C, Fritsch R, et al.
Oncotarget
. 2017 Feb;
8(10):17164-17190.
PMID: 28199979
EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive...
4.
Kovaleva V, Geissler A, Lutz L, Fritsch R, Makowiec F, Wiesemann S, et al.
Mol Cancer
. 2016 Oct;
15(1):63.
PMID: 27756406
Background: Targeted next generation sequencing (tNGS) has become part of molecular pathology diagnostics for determining RAS mutation status in colorectal cancer (CRC) patients as predictive tool for decision on EGFR-targeted...
5.
Lutz L, Fitzner I, Ahrens T, Geissler A, Makowiec F, Hopt U, et al.
Am J Cancer Res
. 2016 May;
6(3):664-76.
PMID: 27152243
Little is known about histone modifiers and histone marks in colorectal cancers (CRC). The present study therefore addressed the role of histone acetylation and histone deacetylases (HDAC) in CRCs in...
6.
Sijare F, Geissler A, Fichter C, Hergeth S, Bogatyreva L, Hauschke D, et al.
Virchows Arch
. 2015 Feb;
466(5):503-15.
PMID: 25680570
Experimental model systems identified phosphorylation of linker histone variant H1.4 at Ser 27 (H1.4S27p) as a novel mitotic mark set by Aurora B kinase. Here, we examined expression of Aurora...